Group 1 - The Federal Reserve is expected to initiate a new round of interest rate cuts, which may lead to a reallocation of international funds, particularly towards emerging markets like China [1] - The Chinese stock market has shown an upward trend, with various indices reaching new highs for the year [1] - Kirsty Desson, head of global small-cap stock investment at Aberdeen Investment, believes that the weak dollar cycle will benefit RMB assets, highlighting potential global investment targets in sectors like biotechnology, consumer applications, and AI in healthcare [1] Group 2 - Since 2025, small-cap stocks have outperformed large-cap stocks, with the Russell 2000 index rising 4.83% in the past month, compared to the S&P 500's 2.1% increase [2] - The MSCI global small-cap index has seen a cumulative increase of 3.67% over the past month and over 11% in three months [2] - Small-cap stocks represent about 15% of the global market capitalization but account for approximately 70% of the total number of listed companies globally [2] Group 3 - The large number of small-cap stocks across various industries provides abundant opportunities for global investors, but selecting quality stocks remains a challenge [3] - The investment philosophy focuses on three key aspects: quality, growth, and momentum [3] - High-quality small-cap stocks can be assessed based on competitive advantages, management capabilities, and financial stability [3] Group 4 - Small-cap stocks are generally more sensitive to interest rate changes, with historical data indicating that they tend to outperform large-cap stocks during the early stages of a rate-cutting cycle [4] Group 5 - There has been a continuous increase in net inflows into emerging market equity funds this year, with a significant rise in funds allocated to Chinese stocks [5] - The A-share market has shown a strong upward trend, with high trading volumes and record inflows from foreign investors [5] Group 6 - The current scale of the Chinese market is relatively small, and many foreign investors are still unfamiliar with it [6] - The shift in global investment patterns from dollar-dominated assets to emerging markets, particularly China, is expected to continue [6] - The "Shanghai-Hong Kong Stock Connect" and "Shenzhen-Hong Kong Stock Connect" have provided effective platforms for foreign investors, enhancing their understanding of the Asian market [6] Group 7 - External factors such as the weakening dollar and geopolitical tensions are prompting investors to reassess their asset allocation strategies [7] - Internal factors like policy adjustments, liquidity improvements, and stronger economic fundamentals are expected to support the Chinese market [7] - The valuation of the A-share market remains attractive, with the CSI 300 index's price-to-earnings ratio around 14 times, still below its five-year average [7] Group 8 - The Chinese capital market is witnessing a revaluation in sectors such as biotechnology, consumer applications, and AI in healthcare [7] - The focus on domestic demand and self-sufficiency is becoming increasingly clear, with innovative Chinese companies, including promising small-cap firms, emerging in the capital market [7] Group 9 - There is an expectation for further favorable policies that will provide more signals regarding growth priorities and consumer orientation, which will bolster market confidence and predictability of corporate earnings [8]

Core Viewpoint - The Ministry of Agriculture and Rural Affairs emphasizes the importance of not only ensuring food security but also improving the nutritional quality of food for the public [1] Group 1: Agricultural Development - The ministry is promoting the transition from traditional crops and livestock to a wider range of biological resources [1] - There is a focus on accelerating the development of biotechnology and the bio-industry, with successful breakthroughs in key core technologies [1] - New types of food are continuously emerging, with algae farming technology being at the forefront globally [1] Group 2: Nutritional Improvement - The nutritional health levels of food consumed by urban and rural residents are becoming more balanced and are approaching those of developed countries [1] - Residents are now not only able to eat enough but also enjoy better and more nutritious food [1]

Group 1: Federal Reserve and Economic Indicators - The Federal Reserve is expected to lower interest rates by 25 basis points, but a larger cut is not completely ruled out [1][2] - Recent inflation data shows a year-on-year CPI increase of 2.9% and a month-on-month increase of 0.4%, indicating the fastest price rise since January [1][2] - The job market is showing signs of weakness, with an average of only 29,000 new jobs added over the past three months, while a monthly addition of 80,000 is needed for economic stability [2][3] Group 2: European Economic Concerns - Fitch downgraded France's long-term sovereign rating from AA- to A+, citing political instability and difficulties in reducing fiscal deficits [3][4] - France's government debt has risen from 94% to 114% over the past decade, with economic growth stagnating around 1% [4][5] - Both France and the UK are facing significant fiscal challenges, with the potential for a slow-burning fiscal crisis if market confidence deteriorates [5][6]

Group 1 - The third Asia Vision Forum, themed "Opportunities in the Era of Change," opened in Singapore with over 400 participants from 12 countries and regions, including government representatives, UN officials, scholars, and business leaders [1] - The three-day forum features more than 30 activities, including keynote speeches, roundtable discussions, and site visits, focusing on Asia's new positioning in the global economy [1] - Key topics of discussion include geopolitical issues, financial markets, corporate internationalization, and critical growth drivers such as artificial intelligence, biotechnology, energy transition, and advanced manufacturing [1] Group 2 - The Asia Vision Forum, initiated by Caixin International and supported strategically by the Singapore government, has become an influential international exchange platform in the region since its inception in 2023 [1]

Core Insights - The trade volume between Guangdong and Taiwan reached 57.8 billion USD in the first half of the year, marking a year-on-year increase of 24.7% [1] - Guangdong has attracted approximately 36,000 Taiwanese-funded enterprises, with actual utilized Taiwanese capital totaling around 73 billion USD [1] - The 16th Dongguan Taiwan Products Expo features over 670 exhibitors and covers an exhibition area of 33,000 square meters, focusing on sectors such as AI, electronic information, intelligent manufacturing, and biotechnology [1] Trade and Investment - The trade volume between Guangdong and Taiwan accounts for about 39% of the total cross-strait trade volume, which is 147.78 billion USD [1] - The Dongguan Taiwan Products Expo is themed "Strong Chain Integration, Intelligent Creation of the Future" and includes eight major theme pavilions and 25 provincial and municipal pavilions [1] Disaster Relief Efforts - Following the severe damage caused by Typhoon "Danas" in southern Taiwan, the Dongguan Taiwanese Business Investment Enterprises Association has facilitated the sale of unsold agricultural products from affected areas at the expo, which has been well-received by mainland consumers [1]

Group 1 - The European Commission is advancing a new round of sanctions against Russia while increasing military and financial support for Ukraine [1] - The recent tariff agreement with the United States is defended as ensuring the best possible outcome for Europe and avoiding a trade war [1] - The establishment of a "European Scale Fund" is announced to facilitate billions of euros in investments in rapidly growing sectors such as artificial intelligence and biotechnology, in collaboration with private investors [1]

Core Insights - International investment banks are showing increased interest in Chinese assets, with U.S. investor attention reaching its highest level since 2021 [1] - Over 90% of investors surveyed by Morgan Stanley expressed willingness to increase exposure to the Chinese market, a significant rise not seen since early 2021 [1] Group 1: Market Trends - Multiple factors are driving this trend, including China's leadership in advanced fields such as humanoid robots, biotechnology, and drug development, positioning the market as a strategic investment choice [1] - Gradual economic stabilization measures and supportive signals from policymakers are enhancing investor confidence [1] - Improved liquidity conditions and the need for diversified global asset allocation are further supporting investment intentions [1] Group 2: Investment Preferences - Investor interest is expanding beyond internet and ADR sectors to include Hong Kong stocks and onshore A-shares, focusing on areas like artificial intelligence, semiconductors, robotics, and new consumption [1] - Quantitative and macro funds are increasingly favoring entry into the market through A-share ETFs and stock index futures for more efficient participation [1] - U.S. investors' trading preferences remain primarily with ADRs, followed by Hong Kong stocks and then A-shares [1]

Core Viewpoint - China's new drug research and development capabilities have risen to the second position globally, with multiple domestic innovative drugs receiving approval for market entry, filling gaps in relevant fields [4][5]. Industry Developments - The National Health Commission announced that the number of new drugs under research in China accounts for over 20% of the global total, marking a significant achievement in the country's pharmaceutical sector [4]. - Several innovative drugs, including Sugliatin, Ensartinib, and Gilteritinib, have been approved and are now available in the market, addressing unmet medical needs [4]. - The self-developed anti-tumor drug, Zebutinib, has also received approval in multiple countries, indicating a successful international expansion [5]. Market Performance - The A-share and Hong Kong stock markets saw a collective downturn in the innovative drug sector, with significant declines in leading stocks [6][7]. - The Hong Kong CRO index dropped by 4.11%, with notable stocks like Gilead Sciences experiencing a decline of over 16% [8]. - By midday, several stocks, including Tigermed and BeiGene, reported declines of over 10% and 6%, respectively, reflecting a broader market weakness [9][11]. Investment Outlook - Despite the current market adjustments, institutions maintain a medium to long-term optimistic outlook for the innovative drug sector [12]. - Reports from Guotai Junan Securities suggest that the quality of financial reports in the innovative drug sector will improve by 2025, with more products entering the national medical insurance system [12]. - Analysts recommend focusing on sectors with strong domestic demand and performance certainty, particularly in innovative-driven and internationalization strategies [12].

Group 1 - The Nasdaq Golden Dragon China Index reached a six-month closing high, rising 1.5% to 8230.86 points on September 9, with Alibaba's ADR increasing by 4.18% and a year-to-date gain of nearly 75% [1] - Morgan Stanley reported that U.S. investor interest in Chinese markets has reached its highest level since 2021, with over 90% of investors expressing willingness to increase exposure to China, a significant rise since early 2021 [1] - Multiple factors are driving this trend, including China's leadership in advanced fields like humanoid robotics and biotechnology, gradual economic stabilization measures from policymakers, improved liquidity, and a demand for diversified global asset allocation [1] Group 2 - Investor interest is expanding beyond internet and ADR sectors to include Hong Kong stocks and onshore A-shares, focusing on areas such as artificial intelligence, semiconductors, robotics, and new consumption [2] - Citigroup forecasts the Hang Seng Index to reach 26,800 points by the end of 2025, with further increases expected in 2026, attributing H-shares to benefit more directly from the Federal Reserve's interest rate cuts [2] - Citigroup emphasizes that the "14th Five-Year Plan" (2026-2030) will focus on economic development, technological innovation, social welfare, green development, and reform, highlighting key industries such as AI, data centers, semiconductors, tourism, healthcare, insurance, and renewable energy [2]

獨家保薦人、獨家保薦人兼整體協調人、聯席全球協調人、 聯席賬簿管理人及聯席牽頭經辦人 勁方醫藥科技 ( 上海 ) 股份有限公司 GenFleet Therapeutics (Shanghai) Inc. 股份代號 : 2595 （於中華人民共和國註冊成立的股份有限公司） 全球發售 重要提示 重要提示：閣下如對本招股章程的任何內容有任何疑問，應尋求獨立專業意見。 GenFleet Therapeutics (Shanghai) Inc. 勁 方 醫 藥 科 技（ 上 海 ）股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） 全球發售 | 全球發售的發售股份數目 | ： | 77,600,000股H股（視乎發售量調整權 | | --- | --- | --- | | | | 及超額配股權行使與否而定） | | 香港發售股份數目 | ： | 7,760,000股H股（可予重新分配） | | 國際發售股份數目 | ： | 69,840,000股H股（可予重新分配及 | | | | 視乎發售量調整權及超額配股權 | | | | 行使與否而定） | | 發售價 | ： | 每股發售股份20.39港元，另加 ...